| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J2502 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
| J1725 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 1 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2012 | In Use | |||
| NA | Fluoxymesterone | Androxy | 10 mg | Hormonal Therapy | Androgen | Yes | 1983 | In Use | ||||
| J9218 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 1 mg | Hormonal Therapy | GnRH Agonist | No | 1995 | Jan 1, 1997 | In Use | |||
| J9395 | Fulvestrant | Faslodex | 25 mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2002 | Jan 1, 2004 | In Use | |||
| NA | Hydrocortisone | Cortef | 5mg, 10mg, 20mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1952 | In Use | |||
| NA | Estrogens, Conjugated | Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) | multiple | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
| NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.3 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
| NA | Flutamide | Euflex, Eulexin | 125 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1989 | In Use | ||||
| J9225 | Histrelin Acetate | Vantas | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| C9454 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
| J9155 | Degarelix | Firmagon | 1 mg | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | No | 2008 | Jan 1, 2010 | In Use | ||
| J2354 | octreotide | sandostatin | 25 mcg | Hormonal Therapy | Somatostatin Analog | No | 1998 | Jan 1, 2004 | In Use | |||
| A9534 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | per MC | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jul 1, 2003 | In Use | |
| A9545 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | Per treatment dose | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jan 1, 2006 | In Use | |
| J9042 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan 1, 2013 | In Use | ||
| Q5129 | Bevacizumab-adcd | Vegzelma | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2023 | Mar 17, 2023 | In Use | ||
| J9345 | Retifanlimab-dlwr | Zynyz | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2023 | Aug 28, 2023 | In Use | ||
| Q2056 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | Sep 27, 2022 | In Use | |||
| Q5114 | Trastuzumab-dkst | Ogivri | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2017 | Jul 1, 2019 | In Use | ||
| NA | Imiquimod | Aldara | 5% | Immunotherapy | Immunomodulator | Retinoic Acid Derivative | No | 1997 | In Use | |||
| Q5158 | Denosumab-bnht | Bomyntra, Conexxence | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| J9273 | Tisotumab vedodin-tftv | Tivdak | 1mg | Immunotherapy | Drug Antibody Conjugate | Tissue factor | No | 2021 | Mar 25, 2022 | In Use | ||
| C9163 | Talquetamab | Talvey | 0.25mg | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
| J9113 | Cemiplimab-rwlc | Libtayo | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2018 | Oct 1, 2019 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home